scholarly journals Product design for people with Rheumatoid Arthritis and its relationship with stakeholder’s expectations

2021 ◽  
Vol 11 (23) ◽  
pp. 13-23
Author(s):  
Allisson José Fernandes De Andrade ◽  
Ricardo Triska
Keyword(s):  
Rheumatoid Arthritis ◽  
User Satisfaction ◽  
Phase 1 ◽  
World Population ◽  
Data Organization ◽  
Independent Manner ◽  
Severe Impairment ◽  
Data Survey ◽  
Advanced Stages ◽  
Reduced Mobility

Approximately 6.2% of the Brazilian population has some disability, from which 1.3% declare to have some physical disability. Rheumatoid Arthritis (RA) is a systemic and autoimmune disease that affects about 0.4% to 1.3% of the world population, being more common in women. In advanced stages, the disease can cause severe impairment in small joints, limiting individuals' movements and impairing their independence and autonomy. Assistive Technology (AT) aims to promote actions that enable People with Disabilities or Reduced Mobility to execute their daily activities in the most normal and independent manner possible. However, studies show high rates of abandonment of AT devices for reasons generally related to the effectiveness of the product itself. Thus, this study aims to carry out data collection, organization, and analysis to understand the expectations of stakeholders about the development of new AT devices for individuals with RA. For this, the technical research procedures were segmented as follows: Phase 1 – Theoretical Foundation; Phase 2 – Selection of Target Audience and Sampling; Phase 3 – Data Survey; and Phase 4 – Data Organization and Analysis. Through the procedures adopted, it was possible to verify that there are significant differences between the expectations of stakeholders concerning the development of new AT products for individuals with RA, which can directly imply user satisfaction, consequently generating the abandonment of these devices if they do not meet the expectations.

scholarly journals AB0655 RHEUMATOID ARTHRITIS ACTIVITY BEFORE AND AFTER COVID-19 LOCKDOWN PERIOD

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 1360.1-1360
Author(s):  
M. Jordhani ◽  
D. Ruci ◽  
F. Skana ◽  
E. Memlika
Keyword(s):  
Rheumatoid Arthritis ◽  
Disease Activity ◽  
Musculoskeletal Diseases ◽  
Statistical Tests ◽  
Laboratory Data ◽  
World Population ◽  
Chronic Patients ◽  
Das 28 ◽  
Significant Difference ◽  
Before And After

Background:The COVID-19 global pandemic has had a great impact on world population due to morbidity, mortality and restriction measures in order to stop the progression of COVID-19.Patients with rheumatic and musculoskeletic diseases, and especially rheumatoid arthritis (RA) patients, being one of the vulnerable classes of chronic patients, were recommended to follow the government’s rules1.Objectives:The aim of this study was to evaluate DAS-28-ESR in patients with rheumatoid arthritis before and after lockdown period.Methods:This is a multi-center observational study including 85 patients which were evaluated before and after lockdown for their disease activity score according to DAS-28-ESR score. They had been diagnosed with rheumatoid arthritis more than 5 years ago. A thorough physical examination was performed before and after the lockdown period. It included examination of tender and swollen joints and patient’s global health. They were completed with all required laboratory data, including erythrosedimentation rate. For a more accurate calculation, DAS-28-ESR was used in an electronic version. Patients with other inflammatory or infective diseases were excluded from the study. All data were statistically evaluated using statistical tests such as t-student test.Results:The first group (the one before lockdown) had an average DAS-28-ESR of 4.7 while after the lockdown period, the average DAS-28-ESR was 5.16.After statistically evaluating all data, it was found that there exists a significant difference between DAS-28-ESR score before and after COVID-19 lockdown (p=0.0011).Conclusion:Our study showed that lockdown period due to COVID-19 pandemic, has aggravated disease activity in patients with Rheumatoid Arthritis. This may be consequence of various causes such as physical inactivity and difficulty to follow-up or to take the medication properly.References:[1]Landewé RB, Machado PM, Kroon F, et al, EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2, Annals of the Rheumatic Diseases 2020;79:851-858.Disclosure of Interests:None declared.

scholarly journals Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure

RMD Open ◽  
2021 ◽  
Vol 7 (2) ◽  
pp. e001595
Author(s):  
Gerd R Burmester ◽  
Peter Nash ◽  
Bruce E Sands ◽  
Kim Papp ◽  
Lori Stockert ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Ulcerative Colitis ◽  
Clinical Trials ◽  
Psoriatic Arthritis ◽  
Adverse Events ◽  
Special Interest ◽  
Phase 1 ◽  
Incidence Rates ◽  
Study Data ◽  
System Organ Class

ObjectivesTo analyse adverse events (AEs) of special interest across tofacitinib clinical programmes in rheumatoid arthritis (RA), psoriatic arthritis (PsA), ulcerative colitis (UC) and psoriasis (PsO), and to determine whether the incidence rates (IRs; unique patients with events per 100 patient-years) of these events are consistent across diseases.MethodsThe analysis included data from patients exposed to ≥1 dose of tofacitinib in phase 1, 2, 3 or 3b/4 clinical trials and long-term extension (LTE) studies (38 trials) in RA (23 trials), PsA (3 trials), UC (5 trials) and PsO (7 trials). All studies were completed by or before July 2019, except for one ongoing UC LTE study (data cut-off May 2019). IRs were obtained for AEs of special interest.Results13 567 patients were included in the analysis (RA: n=7964; PsA: n=783; UC: n=1157; PsO: n=3663), representing 37 066 patient-years of exposure. Maximum duration of exposure was 10.5 years (RA). AEs within the ‘infections and infestations’ System Organ Class were the most common in all diseases. Among AEs of special interest, IRs were highest for herpes zoster (non-serious and serious; 3.6, 1.8, 3.5 and 2.4 for RA, PsA, UC and PsO, respectively) and serious infections (2.5, 1.2, 1.7 and 1.3 for RA, PsA, UC and PsO, respectively). Age-adjusted and sex-adjusted mortality ratios (weighted for country) were ≤0.2 across cohorts.ConclusionsThe tofacitinib safety profile in this analysis was generally consistent across diseases and with longer term follow-up compared with previous analyses.

scholarly journals Artrite Reumatoide e a Poluição do Ar

UNICIÊNCIAS ◽  
2021 ◽  
Vol 24 (2) ◽  
pp. 195-200
Author(s):  
Dayane Dos Santos Souza Magalhães ◽  
Leticia Rosa Espírito Santo de Freitas ◽  
Maria Amélia Dos Santos Peres Santos Souza ◽  
Vander Fernandes ◽  
Walkiria Shimoya-Bittencourt ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Air Pollution ◽  
Disease Activity ◽  
Air Pollutants ◽  
Activity Index ◽  
Age Groups ◽  
Unknown Etiology ◽  
World Population ◽  
Artrite Reumatoide ◽  
The Relationship

A artrite reumatoide é uma doença inflamatória, crônica, autoimune, sistêmica e progressiva com etiologia ainda desconhecida, que causa danos progressivos ao sistema musculoesquelético. Esta doença atinge aproximadamente 0,5% a 1% da população mundial, predomina no sexo feminino e acomete todas as faixas etárias com maior prevalência entre 40-60 anos. A atividade da doença é avaliada pelo Índice de Atividade da Doença (DAS28) analisando 28 articulações. Estudos demonstram que a poluição atmosférica está associada aos agravos à saúde humana e à perda de qualidade de vida. Este estudo teve como objetivo relatar o papel da poluição atmosférica na artrite reumatoide, através de uma revisão narrativa de literatura, a partir das bases de dados PubMed e Scielo. Incluíram-se artigos nos idiomas inglês e português publicados em periódicos, nacionais e internacionais, acerca da temática da pesquisa. A relação entre o desenvolvimento da AR e diferentes poluentes atmosféricos foi analisada em diversos estudos, que demostraram associação entre diferentes poluentes atmosféricos e o desenvolvimento da doença, no entanto, nenhum estudo publicado até a data atual, avaliou a relação com a exacerbação da atividade da doença.   Palavras-chave: Artrite Reumatoide. Poluição do Ar. Doenças Autoimunes.   Abstract Rheumatoid arthritis is an inflammatory, chronic, autoimmune, systemic and progressive disease with a still unknown etiology that causes progressive damage to the musculoskeletal system. This disease affects approximately 0.5% to 1% of the world population, predominates in females and affects all age groups with a higher prevalence between 40-60 years. The disease activity is assessed by the Disease Activity Index (DAS28) analyzing 28 joints. Studies show that air pollution is associated with damage to human health and loss of quality of life. This study aimed to report the role of air pollution in rheumatoid arthritis, through a literature narrative review, using the PubMed and Scielo databases. Articles in English and Portuguese published in national and international journals about the research theme were included. The relationship between the RA development and different air pollutants has been analyzed in several studies, which showed an association between different air pollutants and the development of the disease, however, no study published to date has evaluated the relationship with the disease activity exacerbation.   Keywords: Rheumatoid Arthritis. Air Pollution. Autoimmune Diseases.    

Safety, Tolerability, and Pharmacology of Bortezomib in Cancer Patients with Renal Failure Requiring Dialysis: Results from a Prospective Phase 1 Study.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 3477-3477 ◽  
Author(s):  
Daniel Mulkerin ◽  
Scot Remick ◽  
Chris Takimoto ◽  
Percy Ivy ◽  
Michael Karol ◽  
...  
Keyword(s):  
Renal Impairment ◽  
Dose Escalation ◽  
Severe Renal Impairment ◽  
Phase 1 ◽  
Case Series ◽  
Sensory Neuropathy ◽  
Red Blood Cell Transfusion ◽  
Hematologic Toxicity ◽  
Severe Impairment ◽  
Grade 3

Abstract Background: Bortezomib (btz; VELCADE®) is a specific, reversible proteasome inhibitor approved for the treatment of patients (pts) with multiple myeloma (MM) and mantle cell lymphoma following at least one prior therapy. Retrospective analyses of phase 2/3 studies and case series have shown btz alone or in combination is active and tolerable in MM pts with various degrees of renal impairment, including pts on dialysis. We previously reported clinical and pharmacologic data from the first prospective, dose-escalating study of btz in adult cancer pts with various degrees of renal impairment (ASCO 2006, abstract 2032). Here we present updated safety and tolerability data for dialysis-dependent patients. Methods: Pts with advanced cancer were stratified by renal function into controls and four groups ranging from mild impairment to dialysis dependence. Pts received btz on d 1, 4, 8, and 11 of a 21-day cycle; dose escalation (0.7, 1.0, 1.3 mg/m2) proceeded in cohorts of 3 pts based on dose limiting toxicities (DLTs) observed in cycle 1. Blood samples were taken on d 1 and 8 of cycle 1 for pharmacokinetic (PK) and pharmacodynamic (PD) analysis. Adverse events (AEs) were evaluated using NCI CTC v2.0. DLTs were grade 4 neutropenia for ≥7 d or neutropenic fever, grade 4 thrombocytopenia for ≥7 d, grade 4 hemoglobin for ≥7 d, and grade ≥3 non-hematologic toxicity. Results: To date, 59 pts have been treated, including 16 controls, 34 pts with mild-to-severe impairment, and 9 dialysis pts. Among dialysis pts: 3 were treated at 0.7, 2 at 1.0, and 4 at 1.3 mg/m2; median age was 62 y (range: 42–74); tumor types were MM (n=4), follicular lymphoma (n=1), and solid tumors (n=4). Median number of treatment cycles received was 2 in controls and across renal impairment groups. Dialysis pts received a median of 2 treatment cycles (range: 1–4); 1 pt remains on therapy. Dose escalation was well tolerated, with no DLTs, in pts with mild-to-severe renal impairment. There were no DLTs in cycle 1 in dialysis pts. Toxicities were generally mild in all groups. Among dialysis pts, no unexpected toxicities were seen. One grade 4 treatment-related AE (elevated creatinine) has been reported; grade 3 treatment-related AEs include platelets/thrombocytopenia (3 pts), diarrhea, hemoglobin, leukopenia, lymphopenia, packed red blood cell transfusion, sensory neuropathy, and vomiting (1 pt each). The overall AE profile in dialysis pts was similar to that in controls and in pts with mild-to-severe impairment, although renal and metabolic AEs appeared more common in dialysis pts. Conclusions: Btz at doses up to 1.3 mg/m2 on this schedule was well tolerated in pts with advanced malignancies with mild-to-severe renal impairment and dialysis dependence. PK and PD analyses for dialysis pts treated at 1.3 mg/m2 will be reported. Btz is a viable treatment option for pts requiring dialysis.

scholarly journals Treatment Of Patients With Rheumatoid Arthritis: Real World Population-Based Evidence From France

2017 ◽  
Vol 20 (9) ◽  
pp. A541
Author(s):  
G Mercier ◽  
S Marouen ◽  
G Bourel ◽  
V Georgescu
Keyword(s):  
Rheumatoid Arthritis ◽  
Real World ◽  
Population Based ◽  
World Population

Safety, pharmacokinetics, and efficacy of E6011, an antifractalkine monoclonal antibody, in a first-in-patient phase 1/2 study on rheumatoid arthritis

2017 ◽  
Vol 28 (1) ◽  
pp. 58-65 ◽  
Author(s):  
Yoshiya Tanaka ◽  
Tsutomu Takeuchi ◽  
Hisanori Umehara ◽  
Toshihiro Nanki ◽  
Nobuyuki Yasuda ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Monoclonal Antibody ◽  
Phase 1

scholarly journals Consolidation, Stages of Change, and Loyalty among Users of Public Sports and Health Services Aged 12–16

2021 ◽  
Vol 18 (19) ◽  
pp. 10113
Author(s):  
Antonio Fernández-Martínez ◽  
Luis Alberto Dueñas-Dorado ◽  
María Rosario Teva-Villén ◽  
Alberto Nuviala
Keyword(s):  
Physical Activity ◽  
Health Services ◽  
Stages Of Change ◽  
User Satisfaction ◽  
Specific Activity ◽  
Structural Equations ◽  
Advanced Stages ◽  
The Impact ◽  
The Relationship

There are two main lines of inquiry in the literature on adherence and/or loyalty to the practice of physical activity and to health services: one focuses on the impact of perceived quality of sports and health services and satisfaction with these services on user loyalty, while the other concludes that users with more self-determined motivation at more advanced stages of physical activity display higher levels of physical activity and greater intentions to continue this activity. The objective of this study is to ascertain the impact of different dimensions of sports service quality on satisfaction and loyalty among users aged 12 to 16 years old and to identify any differences between adolescent users at more and less consolidated stages of physical activity. A total of 1717 minors with a mean age of 13.83 ± 1.32 years who practise organised physical activity at public sports centres in Nuevo León (Mexico), 51.5% of whom were boys, participated in the study. The model of structural equations linking quality, satisfaction, and loyalty displayed adequate indices. The results showed that the staff, specific activity, and user satisfaction are predictors of loyalty. Significant differences were only found between minors at consolidated and non-consolidated stages of physical activity in the relationship between service personnel and loyalty. In conclusion, human resources and their deployment are predictive of loyalty towards sports and health services among adolescents.

Sign in / Sign up

Export Citation Format

Share Document